Free shipping on all orders over $ 500

Soticlestat

Cat. No. M21184
Soticlestat Structure
Synonym:

TAK-935; OV935

Size Price Availability Quantity
5mg USD 180  USD180 In stock
10mg USD 290  USD290 In stock
25mg USD 580  USD580 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Soticlestat (TAK-935; OV935) is a first-in-class, potent, selective, orally active inhibitor of cholesterol 24-hydroxylase (CH24H), which is used in the study of epilepsy syndromes.

Chemical Information
Molecular Weight 373.45
Formula C23H23N3O2
CAS Number 1429505-03-2
Solubility (25°C) DMSO ≥ 60 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] Cecil D Hahn, et al. Epilepsia. A phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of soticlestat as adjunctive therapy in pediatric patients with Dravet syndrome or Lennox-Gastaut syndrome (ELEKTRA)

[2] Toshiya Nishi, et al. Epilepsia. Anticonvulsive properties of soticlestat, a novel cholesterol 24-hydroxylase inhibitor

[3] Nicole A Hawkins, et al. Epilepsia. Soticlestat, a novel cholesterol 24-hydroxylase inhibitor, reduces seizures and premature death in Dravet syndrome mice

[4] Adam Strzelczyk, et al. CNS Drugs. Expanding the Treatment Landscape for Lennox-Gastaut Syndrome: Current and Future Strategies

[5] Toshiya Nishi, et al. Sci Rep. Soticlestat, a novel cholesterol 24-hydroxylase inhibitor shows a therapeutic potential for neural hyperexcitation in mice

Related Cytochrome P450 (e.g. CYP17) Products
Cytochrome P450 reductase

Cytochrome P450 reductase is a NADPH-cytochrome reductase.

20-SOLA

20-SOLA is a water-soluble 20-HETE antagonist.

TS-011

TS-011 is a selective inhibitor of 20-hydroxyeicosatetraenoic acid (20-HETE) synthesis.

Dibromo-dodecenyl-methylsulfimide

Dibromo-dodecenyl-methylsulfimide is a selective inhibitor of 20-HETE synthesis and attenuates the vasodilatory response to sodium nitroprusside (SNP).

Abiraterone decanoate

Abiraterone decanoate is a novel, long-acting Abiraterone precursor compound that also exhibits high CYP17 cleavage enzyme inhibition selectivity for prostate cancer related studies.

  Catalog
Abmole Inhibitor Catalog




Keywords: Soticlestat, TAK-935; OV935 supplier, Cytochrome P450 (e.g. CYP17), inhibitors, activators


Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.